Cwm LLC Has $3.05 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Cwm LLC lowered its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 4.4% in the fourth quarter, Holdings Channel reports. The firm owned 38,371 shares of the company’s stock after selling 1,759 shares during the period. Cwm LLC’s holdings in Axsome Therapeutics were worth $3,054,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Washington Trust Advisors Inc. bought a new stake in Axsome Therapeutics during the fourth quarter worth approximately $26,000. Fifth Third Bancorp boosted its position in Axsome Therapeutics by 100.0% during the third quarter. Fifth Third Bancorp now owns 400 shares of the company’s stock worth $28,000 after purchasing an additional 200 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Axsome Therapeutics by 110.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,204 shares of the company’s stock worth $84,000 after purchasing an additional 633 shares during the period. SG Americas Securities LLC bought a new stake in Axsome Therapeutics during the fourth quarter worth approximately $170,000. Finally, Neo Ivy Capital Management bought a new stake in Axsome Therapeutics during the third quarter worth approximately $204,000. Institutional investors own 81.49% of the company’s stock.

Insiders Place Their Bets

In other Axsome Therapeutics news, Director Roger Jeffs sold 29,976 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the completion of the transaction, the director now directly owns 120,756 shares in the company, valued at $8,416,693.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Axsome Therapeutics news, Director Roger Jeffs sold 29,976 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the completion of the transaction, the director now directly owns 120,756 shares in the company, valued at $8,416,693.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Mark L. Jacobson sold 24,662 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $77.24, for a total value of $1,904,892.88. The disclosure for this sale can be found here. Corporate insiders own 24.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. UBS Group initiated coverage on Axsome Therapeutics in a research report on Tuesday, February 6th. They set a “buy” rating and a $111.00 target price for the company. Robert W. Baird initiated coverage on Axsome Therapeutics in a research report on Tuesday, March 19th. They issued an “outperform” rating and a $108.00 price objective for the company. Royal Bank of Canada increased their price objective on Axsome Therapeutics from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. Mizuho increased their price objective on Axsome Therapeutics from $108.00 to $109.00 and gave the company a “buy” rating in a research report on Thursday, March 28th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $119.67.

Axsome Therapeutics Stock Down 2.6 %

Shares of AXSM stock opened at $71.17 on Thursday. The stock has a market cap of $3.37 billion, a P/E ratio of -13.69 and a beta of 1.13. Axsome Therapeutics, Inc. has a one year low of $55.02 and a one year high of $98.40. The stock has a fifty day moving average price of $76.15 and a 200 day moving average price of $75.22. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.63 and a quick ratio of 3.52.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, February 20th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($1.21) by $0.48. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%. The firm had revenue of $71.53 million during the quarter, compared to analysts’ expectations of $70.38 million. Analysts predict that Axsome Therapeutics, Inc. will post -3.81 earnings per share for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.